Nouscom is a cancer vaccine company developing two different approaches using its highly immunogenic viral vectors. Its off-the-shelf cancer vaccine targets subgroups of patients with cancers that have a specific genetic feature (biomarker) called microsatellite instability high, which is associated with a poor prognosis. The company's personalised vaccines use a patient’s own neoantigens (novel cancer-related antigens). These programmes have shown highly promising preclinical results and are both expected to enter the clinic in 2018.

LocationBasel, Switzerland
CEOAlfredo Nicosia
PartnerGenghis Lloyd-Harris
Websitewww.nouscom.com